Brief: FDA Grants Lantern Pharma Orphan Drug Designation For Drug Candidate Lp-284 In High-Grade B-Cell Lymphomas (Hgbl)
30/11/2023 13:09
Lantern Pharma Inc LTRN.O :
* FDA GRANTS LANTERN PHARMA ORPHAN DRUG DESIGNATION FOR DRUG
CANDIDATE LP-284 IN HIGH-GRADE B-CELL LYMPHOMAS (HGBL)
Source text for Eikon: ID:nBw5xwpjha
Further company coverage: LTRN.O
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview